Molecular psychiatry, 2017-05, Vol.22 (5), p.689-702
2017
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Pharmacological enhancement of mGlu5 receptors rescues behavioral deficits in SHANK3 knock-out mice
- Ist Teil von
- Molecular psychiatry, 2017-05, Vol.22 (5), p.689-702
- Ort / Verlag
- England: Nature Publishing Group
- Erscheinungsjahr
- 2017
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- SHANK3 (also called PROSAP2) genetic haploinsufficiency is thought to be the major cause of neuropsychiatric symptoms in Phelan-McDermid syndrome (PMS). PMS is a rare genetic disorder that causes a severe form of intellectual disability (ID), expressive language delays and other autistic features. Furthermore, a significant number of SHANK3 mutations have been identified in patients with autism spectrum disorders (ASD), and SHANK3 truncating mutations are associated with moderate to profound ID. The Shank3 protein is a scaffold protein that is located in the postsynaptic density (PSD) of excitatory synapses and is crucial for synapse development and plasticity. In this study, we investigated the molecular mechanisms associated with the ASD-like behaviors observed in Shank3Δ11 mice, in which exon 11 has been deleted. Our results indicate that Shank3 is essential to mediating metabotropic glutamate receptor 5 (mGlu5)-receptor signaling by recruiting Homer1b/c to the PSD, specifically in the striatum and cortex. Moreover, augmenting mGlu5-receptor activity by administering 3-Cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide ameliorated the functional and behavioral defects that were observed in Shank3Δ11 mice, suggesting that pharmaceutical treatments that increase mGlu5 activity may represent a new approach for treating patients that are affected by PMS and SHANK3 mutations.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1359-4184eISSN: 1476-5578DOI: 10.1038/mp.2016.30Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5014121
- Format
- –
- Schlagworte
- Animals, Autism, Autism Spectrum Disorder - drug therapy, Autism Spectrum Disorder - genetics, Autism Spectrum Disorder - metabolism, Behavior, Behavior, Animal - drug effects, Benzamides - pharmacology, Chromosome Deletion, Chromosome Disorders - genetics, Chromosome Disorders - metabolism, Chromosomes, Human, Pair 22 - genetics, Chromosomes, Human, Pair 22 - metabolism, Corpus Striatum - drug effects, Corpus Striatum - metabolism, Developmental plasticity, Exons, Genetic disorders, Glutamic acid receptors (metabotropic), Haploinsufficiency, Hippocampus - drug effects, Hippocampus - metabolism, Homer Scaffolding Proteins - metabolism, Intellectual disabilities, Laboratories, Male, Mental disorders, Mice, Mice, Inbred C57BL, Mice, Inbred DBA, Mice, Knockout, Microfilament Proteins, Molecular modelling, Mutation, Neostriatum, Nerve Tissue Proteins - deficiency, Nerve Tissue Proteins - genetics, Nerve Tissue Proteins - metabolism, Neurons - drug effects, Neurons - metabolism, Neurosciences, Patients, Post-Synaptic Density - metabolism, Postsynaptic density, Proteins, Pyrazoles - pharmacology, Receptor, Metabotropic Glutamate 5 - metabolism, Signal Transduction, Synaptic Transmission